A Phase I Randomised Trial to Evaluate the Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in Bacille Calmette-Guerin (BCG) Vaccinated Adults
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
Price : $35 *
At a glance
- Drugs IMX-313 (Primary) ; MVA 85A (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- 04 Feb 2016 Results published in the Vaccine
- 15 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Dec 2014 Accrual to date is 100% according to United Kingdom Clinical Research Network.